Availability, Timeliness of Availability of New Cancer Drugs Vary
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 10, 2024 -- Across countries, there are considerable disparities in the availability and timeliness of availability of new cancer drugs, according to a study published online Oct. 8 in BMJ Global Health.
Meng Li, Ph.D., from Tufts Medical Center in Boston, and colleagues examined the availability and timeliness of availability of new cancer drugs between 1990 and 2022. The number of new drugs launched in each country and delay in launches were calculated.
The researchers identified 568 cancer drugs that were launched for the first time globally between 1990 and 2022. Of these, 35, 22, 15, and 28 percent were launched in only one country, in two to five countries, in six to 10 countries, and in more than 10 countries by 2022, respectively. During this period, the number of new drugs launched in a country ranged from 0 to 345. From the first global launch to the second, third, fourth, and fifth launch, the average delays were 18.0, 24.3, 32.5, and 39.4 months, respectively. More launches and shorter delays were seen in association with higher Gross National Income per capita and cancer incidence, respectively.
"Despite considerable progress in the discovery and development of new cancer medicines in recent decades, many of these medicines remained unavailable many years after their first global launch or were only available after long delays," the authors write. "This disparity underscores the need for policy solutions to provide more equitable access to cancer medicines globally."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
CRC as First of Multiple Primary Malignancies Tied to Better Outcomes Than CRC as Only Malignancy
THURSDAY, June 26, 2025 -- Compared with colorectal cancer (CRC) presenting as an isolated primary or second primary malignancy, CRC presenting as the first of multiple primary...
Two-Hour Observation Probably Safe for Most Children With Anaphylaxis
THURSDAY, June 26, 2025 -- For most children who present to an emergency department with an acute allergic reaction requiring epinephrine, a two-hour observation period is...
CT Perfusion and CT Angiography Not Useful as Standalone Tests for Establishing Death by Neurologic Criteria
THURDAY, June 26, 2025 -- Neither computed tomography (CT) perfusion nor CT angiography meet the prespecified validation threshold as an ancillary test for death by neurologic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.